Silver Book Fact

Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.

Neer R, Arnaud C, Zanchetta J, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM. 2001; 344(19): 1434-41. http://content.nejm.org/cgi/content/abstract/344/19/1434

Reference

Title
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Publication
NEJM
Publication Date
2001
Authors
Neer R, Arnaud C, Zanchetta J, et al
Volume & Issue
Volume 344, Issue 19
Pages
1434-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…